<DOC>
	<DOCNO>NCT01687166</DOCNO>
	<brief_summary>The purpose study establish safety effectiveness Blazer Open-Irrigated radiofrequency ablation catheter treatment drug refractory , recurrent , symptomatic , paroxysmal atrial fibrillation .</brief_summary>
	<brief_title>Clinical Evaluation Blazer Open-Irrigated Ablation Catheter Treatment Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>The ZERO-AF trial prospective , multicenter , single blind , 1:1 randomize study . The trial design demonstrate safety effectiveness Blazer® Open-Irrigated Ablation Catheter non-inferior safety effectiveness control catheter , treatment drug refractory , recurrent , symptomatic , paroxysmal atrial fibrillation . The control catheters open-irrigated radiofrequency ablation catheter approve United States treatment drug refractory recurrent symptomatic paroxysmal atrial fibrillation , use compatible three-dimensional electroanatomic mapping system .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Acifluorfen</mesh_term>
	<criteria>History recurrent symptomatic PAF ≥2 episodes report within 365 day prior enrollment PAF AF episode last ≥30 second duration terminate within 7 day . At least 1 episode PAF document Holter monitor , rhythm strip , transtelephonic monitor ( TTM ) , 12lead ECG 365 day prior enrollment Refractory least one Beta Blocker , Calcium Channel Blocker , Class I OR Class III antiarrhythmic drug ( AAD ) Age 18 , legal age give inform consent specific state national law Competent willing provide write informed consent participate study agree comply followup visit evaluation Have follow heart condition within 90 day prior enrollment : New York Heart Association ( NYHA ) Class III IV Left ventricular ejection fraction ( LVEF ) &lt; 35 % Left atrial ( LA ) diameter &gt; 5.5 cm Unstable angina ongoing myocardial ischemia Transmural myocardial infarction ( MI ) Congenital structural heart disease increase risk ablation precludes catheter placement Undergone leave atrial catheter surgical ablation Have coronary intervention , cardiac surgery , cardiac ablation within 90 day prior enrollment Had &gt; 1 AF episode last great 7 day , episode last great 30 day , within past year Subjects regularly prescribe amiodarone therapy 120 day prior enrollment Contraindication anticoagulation therapy Creatinine &gt; 2.5mg/dl creatinine clearance &lt; 30mL/min within 90 day ( 3 month ) prior enrollment Prosthetic mitral tricuspid heart valve Confirmed cardiac thrombus within 30 day ( 1 month ) prior enrollment Implanted pacemaker , ICD , CRT lead within 180 day ( 6 month ) prior enrollment History CVA , TIA PE within 180 day ( 6 month ) prior enrollment Left atrial appendage closure device Any significant uncontrolled unstable medical condition ( e.g . sepsis , acute metabolic illness , end stage COPD ) Enrolled concurrent clinical trial without documented preapproval BSC Women pregnant plan become pregnant within course participation investigation Life expectancy ≤ 2 year ( 730 day ) per physician opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Cardiac Arrhythmias</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Radiofrequency Ablation</keyword>
</DOC>